Abstract
Coronary Artery Disease (CAD) is a prevalent cardiovascular illness that is a primary cause of morbidity and mortality globally. It is distinguished by the constriction or blockage of the coronary arteries, which limits blood circulation to the heart. Inflammation is a driving force in the pathophysiology of CAD. Colchicine is an anti-inflammatory medication that has lately been studied for its potential application in the treatment of CAD. Its multimodal method of action has sparked interest due to its ability to treat inflammation and lower the concentration of critical inflammatory biomarkers. Clinical evidence validates the safe and effective use of Colchicine in CAD. Several recommendations advocate the use of colchicine in the secondary prevention of CAD. This article discusses the use of low-dose colchicine in CAD, its function in inflammation, as well as its safety and therapeutic effectiveness.
Publisher
Innovare Academic Sciences Pvt Ltd
Reference51 articles.
1. Shembade SH, Tadakhe SV, Kore AP. Molecular modeling, synthesis, and antiproliferative evaluation of new isoxazole ring linked by Schiff bases and azo bond. Int J Pharm Pharm Res. 2023;26(3):196-213.
2. Coronary artery disease |cdc.gov. Centers for disease control and prevention; 2021. Available from: https://www.cdc.gov/heartdisease/coronary_ad.htm.
3. Shahjehan RD, Bhutta BS. Coronary Artery Disease. In: StatPearls; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564304 [Last accessed on 05 Apr 2024]
4. Martinez GJ, Robertson S, Barraclough J, Xia Q, Mallat Z, Bursill C. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc. 2015 Aug 24;4(8):e002128. doi: 10.1161/JAHA.115.002128, PMID 26304941, PMCID PMC4599469.
5. Montarello NJ, Singh K, Sinhal A, Wong DTL, Alcock R, Rajendran S. Assessing the impact of colchicine on coronary plaque phenotype after myocardial infarction with optical coherence tomography: rationale and design of the COCOMO-ACS study. Cardiovasc Drugs Ther. 2022 Dec;36(6):1175-86. doi: 10.1007/s10557-021-07240-9, PMID 34432196, PMCID PMC8384919.